The LaPorte plant is a multi-purpose manufacturing facility specialising in the production of registered intermediates and active pharmaceutical ingredients (APIs) for the pharmaceutical industry.
AMPAC Fine Chemicals claimed that the plant is well known for its expertise in performing energetic chemistry at large scale and has been successfully inspected by FDA most recently in 2008.
AMPAC Fine Chemicals added that with equipment, these cGMP manufacturing facilities were completed in 2001 with new equipment added in the last four years. The addition of these facilities increases AMPAC Fine Chemicals’ total reactor capacity by approximately 30%. The LaPorte facilities were purchased by American Pacific Corporation on April 9, 2010 for $475 thousand plus other direct costs.
Aslam Malik, president of AMPAC Fine Chemicals, said: “With the addition of these facilities, we continue to move toward our vision of creating value-added growth in cGMP pharmaceutical chemical manufacturing.
“his additional capability in Texas, which includes commercial scale hydrogenation, as well as azide, cyanide, and phosgene capabilities, fits well with our areas of established expertise in Energetic Chemistry and Continuous Processing. While it will take some time to fill this expanded capacity, our pipeline remains strong and we foresee the need for this capacity as our development products mature.”
Joe Carleone, CEO of American Pacific Corporation, said: “Building new capacity to accommodate future growth just did not make sense to us with excellent facilities sitting relatively idle and available on attractive terms. We are convinced that the pharmaceutical companies will continue to grow their outsourcing strategy for chemicals, especially when unique technologies are involved; as the industry rebounds, we will be there to serve our customers’ increasing needs.”